 Estimating future hepatitis C morbidity, mortality, and costs in the United StatesJ.B. Wong, G.M. McQuillan, J.G. McHutchison and T. Poynard American Journal of Public Health, 2000, vol. 90, issue 10, 1562-1569 Abstract: Obectives: This Study esttmated future morbidity, mortality, and costs resulting from hepatitis C virus (HCV). Methods: We used a computer cohort simulation of the natural history of HCV/n the US population. Results: From the year 2010 through 2019, our model projected 165 900 deaths from chronic liver disease, 27 200 deaths from hepatocellular carcinoma, and $10.7 billion in direct medical expenditures for HCV. Drug this period, HCV may lead to 720 700 years of decompensated cirrhosis and hepatocellular carcinoma and to the loss of 1.83 million years of life in those younger than 65 at a societal cost of $21.3 and $54:2 billion, respectively, sensitivity analysis, these estimates depended on (1) whether patients with HCV and normal transaminase levels develop progressive liver disease, (2) the extent of alcohol ingestion, and (3) the likelihood of dying from other causes related to the rotate of HCV acquisition. Conclusions: Our results confirm prior Centers for Disease Control and Prevention projections and suggest that HCV may lead to a substantial health and economic burden over the next 10 to 20 years. Date: 2000 There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it. Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:aph:ajpbhl:2000:90:10:1562-1569_8 Access Statistics for this article American Journal of Public Health is currently edited by Alfredo Morabia More articles in American Journal of Public Health from American Public Health Association |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.